These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35884213)

  • 21. Determining the Development of Persisters in Extensively Drug-Resistant Acinetobacter baumannii upon Exposure to Polymyxin B-Based Antibiotic Combinations Using Flow Cytometry.
    Wong FH; Cai Y; Leck H; Lim TP; Teo JQ; Lee W; Koh TH; Tan TT; Tan KW; Kwa AL
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymyxin B Combined with Minocycline: A Potentially Effective Combination against bla
    Qu X; Bian X; Chen Y; Hu J; Huang X; Wang Y; Fan Y; Wu H; Li X; Li Y; Guo B; Liu X; Zhang J
    Molecules; 2022 Feb; 27(3):. PubMed ID: 35164349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions of Polymyxin B in Combination with Aztreonam, Minocycline, Meropenem, and Rifampin against Escherichia coli Producing NDM and OXA-48-Group Carbapenemases.
    Olsson A; Hong M; Al-Farsi H; Giske CG; Lagerbäck P; Tängdén T
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0106521. PubMed ID: 34516251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.
    Lenhard JR; Gall JS; Bulitta JB; Thamlikitkul V; Landersdorfer CB; Forrest A; Nation RL; Li J; Tsuji BT
    Int J Antimicrob Agents; 2016 Dec; 48(6):719-724. PubMed ID: 27773498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant
    Zhu S; Zhang J; Song C; Liu Y; Oo C; Heinrichs MT; Lv Z; Zhu Y; Sy SKB; Deng P; Yu M
    Front Microbiol; 2022; 13():1013934. PubMed ID: 36212889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model.
    Lenhard JR; Smith NM; Bulman ZP; Tao X; Thamlikitkul V; Shin BS; Nation RL; Li J; Bulitta JB; Tsuji BT
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052852
    [No Abstract]   [Full Text] [Related]  

  • 27. Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients.
    Heil EL; Claeys KC; Kline EG; Rogers TM; Squires KM; Iovleva A; Doi Y; Banoub M; Noval MM; Luethy PM; Shields RK
    J Antimicrob Chemother; 2023 Apr; 78(4):1034-1040. PubMed ID: 36869724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.
    Hagihara M; Housman ST; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014; 58(2):874-9. PubMed ID: 24277022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
    Wang Y; Li X; Wang D; Sun S; Lu C
    Lett Appl Microbiol; 2020 Mar; 70(3):189-195. PubMed ID: 31808159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant
    Petropoulou D; Siopi M; Vourli S; Pournaras S
    Front Cell Infect Microbiol; 2021; 11():814530. PubMed ID: 35127562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
    Housman ST; Hagihara M; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.
    Yoon J; Urban C; Terzian C; Mariano N; Rahal JJ
    Antimicrob Agents Chemother; 2004 Mar; 48(3):753-7. PubMed ID: 14982760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore.
    Lim TP; Tan TY; Lee W; Sasikala S; Tan TT; Hsu LY; Kwa AL
    J Antibiot (Tokyo); 2009 Dec; 62(12):675-9. PubMed ID: 19876075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients.
    Liang W; Liu XF; Huang J; Zhu DM; Li J; Zhang J
    BMC Infect Dis; 2011 Apr; 11():109. PubMed ID: 21521536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.
    Diep JK; Jacobs DM; Sharma R; Covelli J; Bowers DR; Russo TA; Rao GG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii.
    Mohd Sazlly Lim S; Heffernan AJ; Zowawi HM; Roberts JA; Sime FB
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1943-1952. PubMed ID: 33884516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii.
    Rao GG; Ly NS; Diep J; Forrest A; Bulitta JB; Holden PN; Nation RL; Li J; Tsuji BT
    Int J Antimicrob Agents; 2016 Sep; 48(3):331-6. PubMed ID: 27449542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C; Xie W; Zhang W; Ye Z; Wu H
    Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model.
    Fan B; Guan J; Wang X; Cong Y
    PLoS One; 2016; 11(6):e0157757. PubMed ID: 27315107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the in vitro synergy of polymyxin B-based combinations against polymyxin B -resistant gram-negative bacilli.
    Li Y; Guo S; Li X; Yu Y; Yan B; Tian M; Xu B; Hu H
    Microb Pathog; 2022 May; 166():105517. PubMed ID: 35398467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.